Skip to content

Posts by Arthur Yu-Shin Kim, MD

  • Arthur Y. Kim, MD, COVID medical director of the Department of Medicine at Massachusetts General Hospital, Rajesh Gandhi, MD, director of HIV Clinical Services and Education, and experts from the local Boston community presented on outpatient COVID-19 therapies in the time of omicron.

  • Among patients on supplemental oxygen in the ACTT-1 trial, remdesivir significantly reduced the time to recovery, but, according to Massachusetts General Hospital clinicians, the trial neither demonstrated nor disproved a benefit for sicker or less sick patients.

  • With millions of cases of SARS-CoV-2 infection and nearly 350,000 deaths worldwide due to COVID-19 to date, the need for specific antiviral therapies is imperative. Multiple repurposed or newly developed antiviral treatments have been proposed. Many treatments for COVID-19 have been described in case series and retrospective cohort studies (May 8 FLARE), but few have been tested in a randomized controlled trial (May 11 FLARE). In tonight's FLARE, we review the publication of the Adaptive COVID-19 Treatment Trial-1 (ACTT-1), an RCT that resulted in the emergency use authorization by the U.S. Food and Drug Administration (FDA) for remdesivir (Beigel et al. 2020). 


Arthur Kim, MD, is the Director of the Viral Hepatitis Clinic in the Division of Infectious Diseases at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School. He received his medical degree at Harvard Medical School and trained in internal medicine at Mass General and infectious diseases at MGH/Brigham and Women's Hospital. He expresses a longstanding interest in those living with HCV, especially in special populations such as acute infection, prisoners, post-transplantation, and HIV co-infection. He currently is co-PI or co-investigator of NIH-funded studies examining the immunology and immunogenetics of HCV infection. Dr. Kim serves on the AASLD/IDSA committee that provides online guidance at He focuses on HBV, HCV, and HIV/HCV co-infected patients and especially welcomes referrals of those suspected to have early or acute infection and/or with a history of drug use. Dr. Kim also has many years of experience with inpatient transplant infectious disease and outpatient travel advice.